Quanterix at AAIC 2025

Quanterix will be exhibiting at the Alzheimer’s Association International Conference® (AAIC), the world’s leading conference for dementia science, uniting researchers and clinicians to share breakthroughs in diagnosis, treatment, and care for Alzheimer’s and other dementias. 

Come “All TAUgether Now” to experience:

• Interactive demos of our latest biomarker detection instruments
• Daily open house 12:15 – 2:00 pm: recharge, connect with the Quanterix team, and enjoy lunch on us
• Passport activity with prize giveaways
• A photo moment with our giant TAU display

Visit Us at Booth #1510

Discover how Quanterix’s ultrasensitive biomarker detection technology is accelerating Alzheimer’s research. Engage with our experts, explore key neurology biomarkers, and gain insight into cutting-edge innovations shaping the future of biomarker discovery and precision diagnostics.

Quanterix Product Theatre Presentation

Title: Beyond p-Tau 217: The Need for a Multi-Marker Blood Test in Clinical Dementia Practice

Presenter: Dr. Inge Verberk, PhD – Assistant Professor, Neurochemistry Lab, Laboratory Medicine, Amsterdam UMC

Presentation Overview:
Alzheimer’s disease is the most common form of dementia. Breakthroughs in laboratory technology, such as the development of the Simoa HD-X analyzer, have led to the discovery of blood-based biomarkers that accurately reflect the presence of Alzheimer’s pathology in the brain. Particularly, plasma pTau217 concentrations have a high diagnostic accuracy for Alzheimer’s disease. The clinical dementia practice is however heterogenous, and Alzheimer’s disease is multifactorial in nature. In this presentation, we highlight the need for the use of a multi-marker blood test, extending on plasma pTau217, in clinical dementia practice.